Seasonal Influenza

Comments from Expert Advisory Committee and Key Points from 2017-2018fluvirusimage

  • When influenza A or B is circulating in the community, antiviral therapy should be considered for influenza-like illness in patients who are very ill or who are in recognised risk groups for severe influenza. Information will be issued to GPs when influenza rates increase and antivirals are recommended. See weekly influenza activity reports
  • Previously healthy people (excluding pregnant women ) do not need antiviral treatment unless the clinician feels the patient is very ill or is at serious risk of developing complications from influenza. Symptomatic treatment is the preferred option.
  • Patients who remain unwell after 5 days antiviral treatment need careful clinical assessment. They may have a secondary bacterial infection, or be infected with an antiviral-resistant influenza strain. Specialist consultation is advised especially in immunocompromised or multi-morbidity. There is no evidence that prolonged courses ( > 5 days) antiviral treatment improve outcomes.
    The expert advisory group recommend that these HPSC guidelines are consulted prior to making the final prescribing decision.
  • At risk population: prescribe oseltamivir (PO). Do not wait for laboratory confirmation. Treatment should be started as soon as possible, ideally within 48 hours of onset. There is evidence that treatment may reduce the risk of severe illness up to five days after onset. Severely immunosuppressed patients: prescribe oseltamivir (PO) Rapid emergence of oseltamivir resistance on treatment has been described in these patients and they should be monitored closely. Resistance to oseltamivir has been described in infections from influenza A (H1N1) pdm09 subtype but not in those from influenza A (H3) to date (source: NVRL).
  • Clinicians may consider the use of zanamivir (unlicensed but available inhaler) as first line therapy in immunosuppressed patients with suspected or confirmed influenza A (H1N1) pdm09 based on clinical judgement.
  • Suspected or confirmed oseltamivir resistant influenza in a patient who requires treatment: Zanamivir (unlicensed but available inhaler) 10 mg (2 inhalations) bd. Treatment should be started as soon as possible and ideally within 36 hours of symptom onset.
    Expert advisory group recommend seeking expert advice if considering switch to Zanamivir in immunocompromised
  • More detailed 2017/2018 information on treatment of or chemoprophylaxis for seasonal influenza, including in pregnant or immunosuppressed patients is available in short summary document by clicking here.

back to top


Treatment

Table 1: Antiviral Treatment dosages and schedules for treatment of Children, Adults, Pregnant and immunocompromised
0-12 months6 1-12 years: Dose according to weight below: Adults
(≥13yrs)
10-15kg >15-23kg >23-40kg >40kg
Oseltamivir PO
(treatment course: 5 days)
3mg/kg/
dose bd
30mg bd 45mg
bd
60mg
bd
75mg bd 75mg bd
Zanamivir inhaled (treatment course: 5 days) Not licensed for children <5 years old.
For children aged ≥5 years, Dose:10mg (two 5mg inhalations) bd
10mg
(two 5mg inhalations) bd

Available products:

  • Oseltamivir 30mg , 45mg and 75mg caps
  • Under 1 year olds, oseltamivir powder for oral suspension 6mg/ml.
  • Zanamivir powder for inhalation 5mg per dose. (Not licensed but available)
  • Children over one and adults with swallowing difficulties, and those receiving nasogastric oseltamivir, should use capsules which are opened into an appropriate sugary liquid as oseltamivir has a very bitter taste. If the powder for suspension is used for children over one year of age and/or adults, there may not be adequate quantities of the powder for suspension to meet demand for the under one year age group. It is important that the powder for suspension is reserved for the less than one year age group.’
  • Product information for Tamiflu available at www.medicines.ie
  • Product information for Zanamivir available at www.medicines.ie (not licensed but available)

See guidance on dosing in children for quick reference dosage/weight guide


Table 2: Antiviral dosage and schedules for chemoprophylaxis
Prophylaxis 0->3
months10
>3-11
months
1-12 years: Dose according to weight below Adults
(13 years and over)
≤ 15kg >15-23kg >23-40kg >40kg
Oseltamivir PO
(Prophylaxis course: 10 days)
See footnote 10 below 3mg/kg
od
30mg od 45mg od 60mg od 75mg od 75mg od
Zanamivir INH (Prophylaxis course: 10 days) Not licensed for children <5 years old.
For children aged ≥5 years, 10mg (2 inhalations) od

10mg (2 inhalations) od

Footnote 10: If a child is younger than 3 months old, use of oseltamivir for chemoprophylaxis is not recommended unless situation is judged critical due to limited data in this age group

back to top


Defined Risk Groups for Antivirals

  1. Age 65 years and over
  2. Pregnancy (including up to two weeks post partum), see below.
  3. Children aged <2 years of age
  4. Chronic respiratory disease including those on medication for asthma
  5. Chronic heart, kidney, liver or neurological disease
  6. Diabetes mellitus
  7. Haemoglobinopathies
  8. Immunosuppression (whether due to treatment or disease e.g. HIV)
  9. Morbid obesity (BMI ≥40)
  10. Those with any condition that can compromise respiratory function (e.g. cognitive dysfunction, spinal cord injury, seizure, or other neuromuscular disorder), especially those attending special schools/day centres
  11. Down Syndrome
  12. Children with moderate to severe neurodevelopmental disorders such as cerebral palsy and intellectual disability
  13. Residents of nursing homes or other residential care facilities

The full HPSC Antiviral Treatment of Influenza Guidelines are available here.

All pregnant women with influenza like illness should seek medical advice

  • Antivirals have been recommended for pregnant women due to the adverse clinical outcomes that have been observed for influenza in this group.
  • Oseltamivir remains the first line option for the vast majority of pregnant women with influenza, including during seasons that are dominated by influenza A (H1N1)
  • For pregnant women who meet additional criteria for requiring zanamivir first line, further assessment (i.e. rapid diagnostics) and antiviral treatment should be discussed with a local infection specialist.
  • Oseltamivir is generally well tolerated in patients with influenza, but side effects can occur. There are no data suggesting tolerability differs between pregnant and non-pregnant adults
  • Recent studies suggest there is no evidence of harm in pregnant women treated with oseltamivir or zanamivir (not licensed but available)
  • Chemoprophylaxis is not routinely recommended for pregnant women. However, clinical judgement may be exercised in individual cases if the benefit outweighs the risk.

Patient Information

General Practice Information

Residential Care Facilities

Infection Prevention and Control Advice

Advice for Schools

Reviewed January 2018